CORMEDIX INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.33 USD | -2.20% |
|
-2.02% | +41.76% |
| Apr. 15 | CorMedix's DefenCath Now Commercially Available For US Inpatient Use | MT |
| Apr. 15 | CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath®? (Taurolidine and Heparin) | CI |
Presentation Operator MessageOperator (Operator)Hello, and welcome to the CorMedix Inc. First ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.33
USD
Average target price
13
USD
Spread / Average Target
+143.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +41.76% | 293M | |
| +3.96% | 70.78B | |
| +10.72% | 9.15B | |
| -15.34% | 4.84B | |
| +34.54% | 4.22B | |
| +5.09% | 3.92B | |
| +21.10% | 2.55B | |
| -28.33% | 2.24B | |
| -24.15% | 2.26B | |
| +6.23% | 1.92B |
- Stock Market
- Equities
- CRMD Stock
- News CorMedix Inc.
- Transcript : CorMedix Inc., Q1 2022 Earnings Call, May 12, 2022
